Fc-Engineered Antibodies with Enhanced Fc-Effector Function for the Treatment of B-Cell Malignancies
Monoclonal antibody (mAb) therapy has rapidly changed the field of cancer therapy. In 1997, the CD20-targeting mAb rituximab was the first mAb to be approved by the U.S. Food and Drug Administration (FDA) for treatment of cancer. Within two decades, dozens of mAbs entered the clinic for treatment of...
Main Authors: | Hilma J. van der Horst, Inger S. Nijhof, Tuna Mutis, Martine E. D. Chamuleau |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-10-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/12/10/3041 |
Similar Items
-
ZAP-70 Shapes the Immune Microenvironment in B Cell Malignancies
by: Jingyu Chen, et al.
Published: (2020-10-01) -
Cancer Stem Cells of Differentiated B-Cell Malignancies: Models and Consequences
by: Jean-Jacques Fournie, et al.
Published: (2011-03-01) -
Fc-Engineering for Modulated Effector Functions—Improving Antibodies for Cancer Treatment
by: Rena Liu, et al.
Published: (2020-11-01) -
IgG Fc engineering to modulate antibody effector functions
by: Xinhua Wang, et al.
Published: (2017-10-01) -
Engineering of aglycosylated antibody Fc for effector functions
by: Jung, Sang Taek
Published: (2014)